Navigation Links
Inverseon Announces Positive Phase IIa Asthma Study
Date:1/29/2008

SAN FRANCISCO, Jan. 29 /PRNewswire/ -- Inverseon, Inc. (http://www.inverseon.com) announces the publication of a positive phase IIa clinical trial in asthma.

In the article by Hanania et al., in Pulmonary Pharmacology & Therapeutics, vol. 21, (2008), pp. 134-141, entitled, "The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study," mild asthmatics were treated for 9 weeks. All subjects tolerated the drug, and 8 of 10 subjects experienced a clinically meaningful, dose-related, reduction in airway hyper-responsiveness.

"To our knowledge, this is the first peer-reviewed publication of a clinical trial testing a beta-blocker for the treatment of asthma," commented Richard Bond, PhD, Scientific Founder of Inverseon. "These results lay the groundwork for continuing safety and efficacy studies for a drug that is normally withheld from asthmatics. A similar story played out 10 years ago in congestive heart failure where certain blocker drugs that were once contraindicated are now on the market as the best drugs we have ever had at decreasing mortality in heart failure."

"From receptor theory to animal data and now to clinical data the Inverseon approach is very consistent. In our animal asthma models chronic dosing of beta inverse agonists -- which are a subset of beta blockers -- resulted in up-regulation of lung beta receptors, while reducing inflammation and airway hyper-responsiveness. The fact that we are seeing some of these same changes in human asthmatic subjects is exciting and suggests we may have a way to counteract some of the negative aspects of long-acting beta-agonists and steroids when used in combination with INV102. The data also supports Inverseon's reformulation program for oral controlled-release INV102," commented William J. Garner, MD, Chairman of Inverseon.

About Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD

bill@inverseon.com

http://www.inverseon.com

(212) 222-1188

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
3. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
4. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
5. InterCure Announces 100,000th RESPeRATE Unit Sold
6. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
9. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
10. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2020)... ... , ... Combining multiple food allergies into a single oral ... research scheduled for presentation at the 2020 American Academy of Allergy, Asthma & ... coronavirus disease 2019 (COVID-19). , A retrospective review was used to complete ...
(Date:3/16/2020)... (PRWEB) , ... March 16, ... ... unique, state-of-the-art, integrated, healthcare communication and patient education platform, with content available ... track patient communication, dramatically improving how they support patients before, after, or ...
(Date:3/16/2020)... ... ... The Westat Board of Directors is pleased to announce that Scott Royal, Ph.D., ... Officer (CEO) effective March 16, 2020, replacing CEO James E. Smith, Ph.D., who will ... strong leadership, management, and business development acumen to our company,” said Dr. Smith. “He ...
Breaking Medicine Technology:
(Date:3/28/2020)... ... March 28, 2020 , ... Confluent ... (EPPTS), a physical therapist-owned rehabilitation company since 1985 specializing in the treatment of ... “Since we started more than 30 years ago, we have been committed to ...
(Date:3/27/2020)... LAS VEGAS (PRWEB) , ... March 27, 2020 , ... During a time of global ... high-risk merchant processing, is donating to the UNITE HERE Education and Support Fund ... coronavirus pandemic. , UNITE HERE represents 300,000 working people in the ...
(Date:3/22/2020)... Ill. (PRWEB) , ... March 22, 2020 , ... “At ... if they do not feel well, Preferred Health Insurance Solutions’ First Stop Health ... cold and flu season underway, First Stop Health Telemedicine program, is a valuable tool ...
(Date:3/20/2020)... ... March 20, 2020 , ... The primary objective of ... in machine learning, bioinformatics, immunology, virology and vaccine design to create open source, ... COVID-19 crisis gives us an opportunity and a profound motivation to act selflessly ...
(Date:3/19/2020)... ... March 19, 2020 , ... ... teach Executive Function, shares a free Student Learning Exercise: ExQ® Superpower Hour. ... and teachers are seeking resources to help with the immediate need for activities ...
Breaking Medicine News(10 mins):